International Journal of Clinical Research

Objective To investigate the clinical efficacy of the regimen of lenalidomide combined with bortezomib and dexamethasone in the treatment of myeloma patients and analyze the impact of this regimen on the quality of life of patients. Methods 46 cases of multiple myeloma patients admitted to our hospital from 2024 to December 2024 were selected as cases, and divided into two groups of 23 cases each by random number table method. The experimental was treated with lenalidomide combined with bortezomib and dexamethasone, and the control group was treated with bortezomib combined withamethasone. The treatment efficacy, quality of life scores and incidence of adverse reactions of the two groups were compared. Results The treatment efficacy and quality of life scores of experimental group were higher than those of the control group (P < 0.05), and there was no significant difference in the incidence of adverse reactions between the two (P > 0.05). Conclusion The regimen of lenalidomide combined with bortezomib and dexamethasone is effective in treatment of multiple myeloma, can improve the treatment efficacy and the quality of life of patients, and its safety is comparable to that of conventional regimens, which has the value clinical promotion and application.

Lenalidomide; Bortezomib; Dexamethasone; Multiple myeloma; Treatment effic; Quality of life